Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCerillion Regulatory News (CER)

Share Price Information for Cerillion (CER)

Share Price is delayed by 15 minutes
Get Live Data
1,247.50    5.00 (0.40%)
Bid:
1,235.00
Ask:
1,260.00
Spread: 25.00 (2.024%)
Market Cap: £369.26m
CER Live PriceLast checked at - London Stock Exchange

Intraday Cerillion Share Chart

Further concentrate purchase

1 Oct 2007 07:02

Celtic Resources Holdings PLC01 October 2007 1 October 2007 Celtic Resources Holdings Plc ("Celtic" or the "Company") Celtic enters into agreement to purchase concentrates Celtic is pleased to announce that it has entered into an agreement with asubsidiary of European Goldfields Limited, Hellas Gold S.A. ("Hellas Gold"), forthe purchase of 50,000 tonnes of concentrates containing approximately 30,000 ozof gold. As announced on 22 September 2006, the Company acquired 9,000 tonnes ofconcentrate containing approximately 6,000 oz of gold, to be processed on atrial basis, by Celtic at its Suzdal BIOX(R) plant in Kazakhstan. The Companyalso announced that, if the initial shipments proved successful, it intended topurchase up to an additional 120,000 tonnes of concentrates from Hellas Gold.The Company has been very satisfied by the results of the trial and is thereforeannouncing an agreement to purchase a further 50,000 tonnes of concentrates,with shipments expected to be completed by the end of September 2009. The Company operates the only BIOX(R) plant in the FSU for the treatment ofrefractory sulphide ores and in addition to treating ore produced at its Suzdalmine, it will be utilising available BIOX(R) capacity to produce more gold. Suzdal has produced over 28,599 oz of gold in the last three months, whichincludes 11,780 oz produced in September, at an average sale price of US$718 peroz. Kevin Foo, Managing Director of Celtic, said, "We have been delighted with theresults of our initial trial to process third party concentrates at our SuzdalBIOX(R) plant. This agreement is a significant step forward in our strategy tocapitalise on our technology advantages at Suzdal and we are also looking atother third party concentrate opportunities within Kazakhstan and Russia, asmany refractory gold ores remain unexploited." Contact information: Kevin Foo / Jonathan Scott-BarrettCeltic Resources Holdings PlcTel: + 44 (0)20 7921 8800Investors@celtic resources.com Leesa Peters / Jane StaceyConduit PRTel: +44 (0)20 7429 6606 / (0)792 292 3306leesa@conduitpr.com Anthony CardewCardew GroupTel: +44 (0)20 7930 0777anthony.cardew@cardewgroup.com Strand Partners LimitedSimon RaggettStuart FaulknerTel: +44 (0)20 7409 3494 About the Suzdal BIOX(R) plant: Celtic has successfully developed the first BIOX(R) plant for treatment ofrefractory sulphide ores in the FSU at its Suzdal mine in Kazakhstan. The plantuses a sulphide oxidation process for recovering gold from refractory ores orconcentrates. The process utilises a mixed population of naturally occurringbacteria, that are present in all sulphide ores, to break down the sulphidemineral matrix, thereby liberating the occluded gold for subsequent cyanidation. The BIOX(R) process acts as an alternative to conventional processes of roastingand pressure oxidation and offers advantages of reduced capital cost, simplicityof operations, robustness and very low environmental impact. Any person who is the holder of 1 per cent. or more of any class of shares inCeltic may be required to make disclosures pursuant to Rule 8.3 of the IrishTakeover Panel Act, 1997, Takeover Rules 2001 to 2006. The Directors of Celtic accept responsibility for the information contained inthis announcement and to the best of their knowledge and belief (having takenall reasonable care to ensure that such is the case), the information containedin this announcement is in accordance with the facts and, where appropriate,does not omit anything likely to affect the import of such information. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Feb 20209:57 amRNSResult of AGM
8th Jan 20208:58 amRNSHolding(s) in Company
8th Jan 20207:00 amRNSNotice of AGM
27th Nov 20192:52 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSFinal Results
20th Nov 20197:00 amRNSHolding(s) in Company
28th Oct 20197:00 amRNSTrading Update
14th Oct 20197:00 amRNSMajor Contract Win
26th Sep 20194:49 pmRNSHolding(s) in Company
9th Sep 20197:00 amRNSMajor New Contract Win
8th Aug 20194:14 pmRNSHolding(s) in Company
8th Aug 20194:13 pmRNSHolding(s) in Company
28th Jun 20197:00 amRNSHolding(s) in Company
25th Jun 20197:00 amRNSMajor Contract Win
14th Jun 20197:00 amRNSMajor New Contract Win
20th May 20197:00 amRNSInterim Results
2nd May 20197:00 amRNSTrading Update and Notice of Results
21st Feb 20197:00 amRNSGartner Magic Quadrant Report
14th Feb 20194:01 pmRNSEmployee Share Option Scheme
13th Feb 20197:00 amRNSMajor New Contract Win
8th Feb 20193:16 pmRNSResult of AGM
25th Jan 20196:03 pmRNSNotice of AGM
26th Nov 20187:00 amRNSFinal Results
22nd Oct 20187:00 amRNSTrading Update
30th May 20187:00 amRNSTM Forum's 2018 Catalyst Awards
14th May 20187:00 amRNSInterim Results
16th Apr 20187:25 amRNSTrading Update & Notice of Results
5th Feb 201810:21 amRNSResult of AGM
17th Jan 20187:00 amRNSNotice of AGM and Posting of Annual Report
5th Dec 20177:00 amRNSMajor Contract Win
27th Nov 20177:00 amRNSFinal Results
17th Nov 20177:00 amRNSChange of Registered Office
30th Oct 20177:00 amRNSGartner Magic Quadrant Report
30th Oct 20177:00 amRNSTrading Update
20th Sep 20174:33 pmRNSHolding(s) in Company
19th Sep 20174:39 pmRNSImplementation of Long Term Incentive Plan
26th May 201710:13 amRNSCompletion of Director Placing
25th May 20175:00 pmRNSProposed Director Placing
22nd May 20177:00 amRNSInterim Results
9th May 20177:00 amRNSNotice of Results
10th Apr 20177:00 amRNSTrading Update
17th Mar 20177:00 amRNSMajor Contract Win
8th Feb 20174:11 pmRNSRe: New Employee Share Option Scheme
11th Jan 20175:47 pmRNSNotice of AGM and Posting of Annual Report
6th Jan 20177:00 amRNSNew Employee Share Option Scheme
21st Dec 20167:00 amRNSMajor Contract Win
1st Dec 20165:38 pmRNSRevised Dividend Timetable
28th Nov 20167:00 amRNSMajor Contract Win
28th Nov 20167:00 amRNSFinal Results
24th Oct 20167:00 amRNSRe: Gartner's 2016 Magic Quadrant report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.